Current and future therapies for small cell lung carcinoma
Top Cited Papers
Open Access
- 1 April 2025
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 18 (1) , 1-37
Abstract
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid proliferation and high metastatic potential. It is characterized by universal inactivation of and RB1, overexpression of the MYC family and dysregulation of multiple oncogenic signaling pathways. Among different patients, SCLCs are similar at the genetic level but exhibit significant heterogeneity at the molecular level. The classification of SCLC has evolved from a simple neuroendocrine (NE)/non-neuroendocrine (non-NE) classification system to a transcription factor-based molecular subtype system; lineage plasticity adds further complexity and poses challenges for therapeutic development. While SCLC is initially sensitive to platinum-based chemotherapy, resistance develops rapidly, leading to a dismal prognosis. Various antibodies, including PD-1/PD-L1 inhibitors and antibody‒drug conjugates, have been introduced into clinical practice or are being evaluated in clinical trials. However, their therapeutic benefits for SCLC patients remain limited. This review summarizes SCLC carcinogenic mechanisms, tumor heterogeneity, and the immune microenvironment of SCLC, with a focus on recent advances in metastasis and resistance mechanisms. Additionally, the corresponding clinical progress in tackling these challenges is discussed.Keywords
Funding Information
- China Postdoctoral Science Foundation (2023M742488)
- the Sichuan Science and Technology Program (24NSFSC6690, 2025ZNSFSC0047)
- "From 0 to 1" innovative research project of Sichuan University (2023SCUH0031)
- the Post-Doctor Research Project, West China Hospital, Sichuan University (2023HXBH004)
- The National Natural Science Foundation of China (82470188, T2221004)
- the 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYGD22012)
- The National Science and Technology Major Project of China (2024YFF0507400)
- the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation (TFJC2023010004)
- National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Z2024JC001)
This publication has 331 references indexed in Scilit:
- Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung CancerJAMA Oncology, 2025
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivoJournal of Leukocyte Biology, 2022
- Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulationMolecular Oncology, 2020
- Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distributionMolecular Oncology, 2020
- Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic PatientsJAMA Oncology, 2020
- A time for YAP1: Tumorigenesis, immunosuppression and targeted therapyInternational Journal of Cancer, 2018
- Roles of Chk1 in cell biology and cancer therapyInternational Journal of Cancer, 2013
- The fate is not always written in the genes: Epigenomics in epidemiologic studiesEnvironmental and Molecular Mutagenesis, 2013
- The role of RAD51 in etoposide (VP16) resistance in small cell lung cancerInternational Journal of Cancer, 2003